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CuATSM Protects Against the in Vitro Cytotoxicity of Wild-Type-Like
Copper-Zinc Superoxide Dismutase Mutants but not Mutants That
Disrupt Metal Binding
Abstract

Mutations in the SOD1 gene are associated with some forms of familial amyotrophic lateral sclerosis (fALS).
There are more than 150 different mutations in the SOD1 gene that have various effects on the copper-zinc
superoxide dismutase (SOD1) enzyme structure, including the loss of metal binding and a decrease in dimer
affinity. The copper-based therapeutic CuATSM has been proven to be effective at rescuing neuronal cells
from SOD1 mutant toxicity and has also increased the life expectancy of mice expressing the human
transgenes SOD1G93A and SOD1G37R. Furthermore, CuATSM is currently the subject of a phase I/II
clinical trial in Australia as a treatment for ALS. To determine if CuATSM protects against a broad variety of
SOD1 mutations, we used a well-established cell culture model of SOD1-fALS. NSC-34 cells expressing
SOD1-EGFP constructs were treated with CuATSM and examined by time-lapse microscopy. Our results
show a concentration-dependent protection of cells expressing mutant SOD1A4V over the experimental time
period. We tested the efficacy of CuATSM on 10 SOD1-fALS mutants and found that while protection was
observed in cells expressing pathogenic wild-type-like mutants, cells expressing a truncation mutant or metal
binding region mutants were not. We also show that CuATSM rescue is associated with an increase in human
SOD1 activity and a decrease in the level of SOD1 aggregation in vitro. In conclusion, CuATSM has shown to
be a promising therapeutic for SOD1-associated ALS; however, our in vitro results suggest that the protection
afforded varies depending on the SOD1 variant, including negligible protection to mutants with deficient
copper binding.
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Abstract
Mutations in the SOD1 gene are associated with some forms of familial ALS (fALS). There are
over 150 different mutations in the SOD1 gene which cause various effects to the SOD1 enzyme
structure, including loss of metal binding and a decrease in dimer affinity. The copper-based
therapeutic CuATSM has been proven to be effective at rescuing neuronal cells from SOD1 mutant
toxicity, and has also increased the life expectancy of mice expressing the human transgenes
SOD1G93A and SOD1G37R. Furthermore, CuATSM is currently the subject of a phase I/II clinical
trial in Australia as a treatment for ALS. In order to determine if CuATSM protects against a broad
variety of SOD1 mutations, we used a well-established cell culture model of SOD1-fALS. NSC34 cells expressing SOD1-EGFP constructs were treated with CuATSM and examined by time
lapse microscopy. Our results show a concentration dependent protection of cells expressing
mutant SOD1A4V over the experimental time period. We tested the efficacy of CuATSM on ten
SOD1-fALS mutants and found that while protection was observed in cells expressing pathogenic
wild type-like mutants, cells expressing a truncation mutant or metal binding region mutants were
not. We also show that CuATSM rescue is associated with an increase in human SOD1 activity
and a decrease in SOD1 aggregation in vitro. In conclusion, CuATSM has shown to be a promising
therapeutic for SOD1-associated ALS, however, our in vitro results suggest that the protection
afforded varies depending on the SOD1 variant, including negligible protection to mutants with
deficient copper binding.

Graphical Abstract

Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease and is the most
common type of Motor Neuron Disease. ALS causes loss of muscle control and eventually leads
to death due to respiratory failure, generally within 3-5 years after diagnosis1. These symptoms
manifest due to the degeneration of upper and lower motor neurons in the motor cortex and spinal
cord. The lifetime risk for ALS is ~1:300 to 1:4002, and currently there are no effective treatments.
Most cases of ALS are sporadic (sALS), however, approximately 10% are inherited. These familial
cases (fALS) are linked to mostly missense mutations in over a dozen genes, including SOD13,
TARDBP4, FUS5,6 and CCNF7. Furthermore, the most common genetic cause of ALS results from
hexanucleotide repeats in non-coding regions of the C9ORF72 gene8,9.
SOD1 was the first gene identified to contain mutations associated with fALS3 and is the most
widely studied of the currently known ALS-associated genes. Over 150 (mostly missense)
mutations occurring throughout the protein sequence are currently thought to be fALS causative,
with these mutations being responsible for ~20% of fALS cases10. The SOD1 gene encodes an
antioxidant enzyme, copper-zinc superoxide dismutase (SOD1), which functions as a cytosolic
free radical scavenger. The protein has a homodimeric structure where monomers contain an
intramolecular disulfide bond and also bind one copper (Cu) atom and one zinc (Zn) atom11. The
maturation pathway of SOD1 is thought to proceed through Zn binding to the nascent
polypeptide12, followed by association with the copper chaperone for SOD1 (CCS), which delivers
Cu and facilitates disulfide formation13. Cu is essential for its superoxide scavenging role as it
reacts with oxygen free radicals in the following Cu-dependent reactions14:
1.
2.

O2•- + CuIIZnSOD → O2 + CuIZnSOD
O2•- + 2H+ + CuIZnSOD → H2O2 + CuIIZnSOD

It was initially thought that loss of enzymatic function was responsible for disease, however, this
was determined not to be the case as many SOD1-fALS mutants retain enzymatic activity at near
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wild type levels15. SOD1-fALS mutations are broadly designated into two classes; (i) wild typelike (WTL), which have similar dismutase activity levels to the wild type protein, and (ii) metal
binding region (MBR) which are mutations occurring within the metal binding region of SOD1
that disrupt proper coordination of either Zn or Cu, resulting in decreased folding stability and
enzymatic activity11. The existence of the WTL mutants suggests that pathology is caused by a
toxic gain of function, most likely due to the misfolding and subsequent aggregation of mutant
SOD111.
Growing evidence suggests that there is an association between protein aggregate formation and
the development of ALS16. In SOD1-fALS it has been shown that affected neurons often have
proteinaceous inclusions primarily composed of SOD1, and the aggregation propensity of SOD1
mutants correlate with cell death in vitro17. Also, the prion-like propagation of SOD1 misfolding
and aggregation has been proposed to explain the progressive nature of the disease18-21.
Aggregation of the SOD1 enzyme is generally associated with mutations that result in the
destabilization of the structure from decreased metal binding22, defective disulfide bond
formation23, increased dimer dissociation24, and monomeric folding stability25. In addition, SOD1
is significantly metastable in motor neurons owing primarily to its extremely high expression26
making it prone to aggregation, and it is expected that mutations act to exacerbate this situation.
Recently, the Cu-based small molecule Cu(II)ATSM (CuATSM) has been used experimentally to
rescue ALS phenotypes in cell and mouse models27-29. Furthermore, human trials are currently
underway as a potential treatment for ALS26. In separate experiments, CuATSM was shown to
increase the survival of mice overexpressing the human SOD1 transgene with G37R 28,29 or G93A
27,30
mutations, both of which are WTL mutants. CuATSM was effective in protecting against
SOD1-fALS mediated pathology in these experiments, however, since both mutations tested were
WTL11, whether CuATSM is still effective against MBR mutants is unknown. Therefore, using an
established cell model of SOD1-related fALS17,31,32, we set out to investigate whether CuATSM
is protective across a range of ALS-associated SOD1 mutations. In the current work, ten SOD1fALS mutations (SOD1A4V, SOD1G127X, SOD1C6G, SOD1G37R, SOD1H46R, SOD1E100G, SOD1D90A,
SOD1G93A, SOD1V148G and SOD1G85R) and wild type SOD1 (SOD1WT) were used to examine
mutant specific effects of CuATSM treatment (Figure 1). We found that of these mutants, cells
expressing SOD1H46R, SOD1G127X and SOD1G85R, all which have disrupted Cu binding, were not
protected by CuATSM. Further, we found that CuATSM significantly reduces the aggregation of
pathogenic WTL mutants. These results are consistent with CuATSM delivering Cu to mutant
SOD1 when Cu binding is not impaired, increasing protein stability, reducing aggregation and
improving cell survival.
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Figure 1: SOD1 dimer with post-translational modifications and ALS-associated mutants. (Left
subunit) The location of the wild-type like (WTL) SOD1 mutants examined in this study (red spheres).
(Right subunit) Cu (blue sphere) and Zn (green sphere) ions in their native binding sites. The metal-binding
region (MBR) mutants H46R and G85R (magenta) shown close to the metal-binding pocket. The truncation
mutant G127X is shown as an orange sphere. The disulfide bond is shown on both subunits (yellow sticks).
PDB accession: 1HL5 33.

Results and Discussion
The therapeutic benefits of CuATSM have been experimentally proven in multiple models of
SOD1-fALS27-30, and independently verified in the SOD1-G93A mouse model34, however, the
exact mechanism of action in these models remains to be elucidated. Previous in vivo studies have
used CuATSM on SOD1-fALS mice carrying transgenes for the WTL mutants SOD1G37R 29 and
SOD1G93A 30, however, no experiments have been performed in models expressing SOD1 MBR
mutants. Here, we have addressed this gap in knowledge by using CuATSM to treat a cell model
of SOD1-fALS that allowed for rapid comparison of a broad range of mutants, finding that
CuATSM alleviated pathology only for pathogenic WTL SOD1 mutants.
CuATSM protects NSC-34 cells against mutant SOD1 toxicity in a dose dependent manner.
CuATSM has been shown to improve survival and locomotor function of SOD1 mice in a dosedependent manner29. Here we sought to determine the effect of CuATSM on the survival of a wellestablished cell model; NSC-34 cells overexpressing human mutant SOD1-EGFP17,31. Using livecell time-lapse microscopy we monitored the survival of NSC-34 cells transiently transfected with
SOD1WT-EGFP (Figure 2A), SOD1A4V-EGFP (Figure 2B) or EGFP only control (Figure 2C)
over a 90 h period in the presence of increasing concentrations (0 - 1 µM) of CuATSM. Consistent
with what has been observed in transgenic SOD1 animal models29, CuATSM increased the
survival of mutant SOD1 expressing NSC-34 cells in a dose dependent manner. In the absence of
CuATSM, SOD1A4V-EGFP expression resulted in a significant loss of cells compared to those
expressing SOD1WT-EGFP. A concentration dependent increase in SOD1A4V-EGFP cell numbers
was observed post CuATSM treatment, except for at the 1 µM dose which resulted in a loss of
cells relative to the 0.5 µM dose (Figure 2D). The protection afforded to SOD1A4V-EGFP
expressing cells by CuATSM was maximal at 0.5 µM. Treatment with 1 µM CuATSM was also
toxic to cells expressing both SOD1WT-EGFP and EGFP. Therefore, a CuATSM concentration of
3

0.5 μM was selected as the most appropriate dose to examine the toxicity associated with
overexpression of mutant SOD1 in NSC-34 cells for subsequent experiments.

Figure 2: The effects of CuATSM on the survival of NSC-34 cells expressing SOD1-EGFP. NSC-34
cells expressing SOD1WT (A), SOD1A4V (B) and EGFP (C) were treated with 0-1μM CuATSM and images
were acquired for 90 h every 3 h on a IncuCyte automated fluorescent microscope in the GFP channel. The
number of GFP positive cells was determined at every time point and first normalized to the starting time
point after which the value at each time point for mutants was normalized to the number of untreated
SOD1WT cells at corresponding time points (indicated by the solid straight line in panels B and C). (D) The
percentage survival of cells expressing SOD1WT, SOD1A4V or EGFP in the presence of 0-1μM CuATSM
was determined by measuring the area under the GFP count curves and normalizing to SOD1WT in the
absence of CuATSM. Data shown are means ± SEM (n= 3). Each sample is an individually treated single
microplate well. Two-way ANOVA with Bonferroni post-test was used to compare differences. Asterisks
indicate a significant difference to SOD1WT (*p<0.05, ***p < 0.001).

CuATSM does not protect cells expressing SOD1 mutations that disrupt metal binding.
Although CuATSM has been previously shown to rescue SOD1 mouse models from
overexpression of either SOD1G37R 28,29 or SOD1G93A 27-30, it has not been tested against other
4

SOD1 mutations, some of which are MBR mutations which affect Cu coordination. Having
determined an effective dose of CuATSM to apply to our model, we transiently transfected NSC34 cells with ten different mutant SOD1-EGFP constructs to determine the effect of CuATSM on
a range of SOD1 mutants, including MBR mutations.
As we have shown previously, expression of human SOD1 mutants result in a loss of cell numbers
relative to cells expressing SOD1WT 17. An exception to this is the D90A mutation which is
recessive in some Scandinavian families35. In fact, the pathogenic nature of D90A is contested,
with some suggesting heterozygosity is enough to cause disease36, while others have found that as
many as 2.5% of the Northern Swedish population are carriers, suggesting D90A is not
pathogenic37. Consistent with this is the fact that some D90A kindreds individuals without the
mutation inherit ALS38. Our results are consistent with the latter in that expression of SOD1D90A
did not produce a phenotype, and as such essentially acts as an additional WT control. In the case
of cells expressing EGFP fused to SOD1A4V, SOD1C6G, SOD1G37R, SOD1E100G, SOD1G93A, and
SOD1V148G, the addition of 0.5 μM CuATSM resulted in an increased number of SOD1-EGFP
positive cells comparative to untreated cells at all time points (Figure 3A). After calculating the
area under the curve across the entire time course, it is apparent that CuATSM treatment
significantly improved transfected cell survival for these mutants (Figure 3B).
Cells transfected with MBR mutants SOD1H46R and SOD1G85R also exhibited a loss of transfected
cells relative to SOD1WT over time. Similarly, the truncation mutant SOD1G127X, that fails to fold
and thus should not bind metals, also resulted in relative cell loss. However, addition of CuATSM
did not alter the rate of cell loss (Figure 3A) and no significant differences in cell survival were
observed with the addition of CuATSM in these mutants (Figure 3B). Cells expressing SOD1D90A,
EGFP or SOD1WT also were also unaffected by CuATSM but this was most likely due to the fact
that expression of these constructs did not result in a significant loss of cells when left untreated.
Each pathogenic SOD1 mutant elicited a variable effect on relative NSC-34 cell survival
(Supplementary Figure 1). In order to compare the amount of protection afforded to each mutant
by CuATSM, a protection score (% protection) was calculated. The score represents the percentage
protection CuATSM provides to cells compared to the vehicle control, regardless of differences in
cell loss from SOD1WT. This allows for direct comparisons across SOD1 variants. The analysis
confirmed that cells expressing SOD1G127X, SOD1H46R, and SOD1G85R were not protected by
CuATSM (Figure 3C). Cells expressing SOD1WT, SOD1D90A or EGFP were also not protected by
CuATSM treatment. For all other SOD1 mutants, CuATSM had a significant protective effect on
cell survival. Protection scores for these WTL mutants ranged from ~50% (SOD1V148G) to ~85%
(SOD1G93A), suggesting CuATSM does not provide protection to all WTL mutants equally (Figure
3C, Supplementary Table 1). However, there was no relationship between protection score and
associated clinical disease severity (Supplementary Figure 2).
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The results reported here show that addition of CuATSM to cells expressing MBR SOD1-fALS
mutants and truncation mutant SOD1G127X does not alleviate the toxicity of these mutant proteins.
Furthermore, CuATSM does not affect cells expressing EGFP, SOD1D90A, or SOD1WT. However,
similar to previously published data from mouse models27-30, we show that CuATSM improves the
survival of cells expressing pathogenic WTL SOD1 mutants.

6
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Figure 3: The effect of CuATSM on the toxicity of different SOD1 variants. (A) NSC-34 cells were
transfected with SOD1-EGFP constructs and GFP fluorescence was monitored over 120 h in the presence
and absence of 0.5μM CuATSM. (B) Cell survival compared to cells expressing SOD1WT was determined
by measuring the area under the curve for each SOD1 variant in the presence and absence of CuATSM over
the 120 h time period. Data shown are means ± SEM (n= 3). Each sample is an individually treated, single
microplate well. Data are representative of 3 independent experiments. Statistical significance was
determined using two-way ANOVA with Bonferroni post-test (*** p < 0.001). (C) The protection provided
to cells by CuATSM was determined by calculating the difference between each variant with and without
CuATSM treatment as a percentage relative to untreated cells. Data shown are means ± SD (n= 3). Each
sample is an individually treated, single microplate well. Data are representative of 3 independent
experiments. Statistical significance was determined using one-way ANOVA with a Tukey’s multiple
comparison post-test. Asterisks indicate significant difference to SOD1WT (*** p < 0.001).

CuATSM decreases the aggregation of SOD1 mutants in cultured cells.
Although SOD1 is a small protein, it requires extensive processing and post-translational
modification (PTM) to reach maturity13, which includes Zn binding, Cu binding, and disulfide
formation. These PTMs impart remarkable stability to the enzyme making it resistant to proteolytic
digestion39, thermal unfolding40, and chemical denaturation41. Removal of these PTMs is
considered necessary for its misfolding and aggregation42. Indeed, the thermal stability of mature
mutant SOD1G93A is highly similar to SOD1WT 43, with significant differences between the stability
of mutants only becoming apparent in the apo-state. Considering this, the availability of additional
Cu imparted by CuATSM treatment, would be expected to aid CCS in its chaperone function44
and increase maturation of the pool of intracellular SOD1 to a Cu bound form that is less
susceptible to misfolding and aggregation.
To test whether CuATSM affects the aggregation of SOD1 in the NSC-34 cell model, cells
expressing the various SOD1-EGFP constructs were treated with 0.5 μM CuATSM for 72 h before
permeabilising cell membranes with saponin45,46 to allow the diffusion of soluble protein out of
the cell and facilitate examination of the insoluble EGFP signal remaining inside the cell47 (Figure
4A). The amount of insoluble material (aggregates) remaining inside cells was then quantified as
a proportion of transfected cells. We found that aggregation varied amongst SOD1 variants with
as many as 22% of SOD1A4V expressing cells, and ~1% of SOD1WT and SOD1D90A expressing
cells containing aggregates (Figure 4B). In cells where minimal aggregation occurred, specifically
EGFP, SOD1WT and SOD1D90A, CuATSM had no significant effect on aggregation. We also found
that CuATSM did not significantly reduce the aggregation of MBR SOD1 mutants SOD1H46R and
SOD1G85R (1.2 and 1.1 fold reduction in the percentage of cells containing aggregates compared
to the vehicle control respectively; Figure 4B). Cells expressing the largely unstructured
SOD1G127X also had a small but significant decrease in aggregation in the presence of CuATSM
(~ 1.3 fold reduction). In contrast, cells expressing pathogenic WTL mutants all showed a
significant reduction in cells containing aggregates (on average ~ 3 fold reduction, also see
Supplementary Table 1) distinguishing them from the MBR mutants and controls (Figure 4B).
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Although Cu deficiency is associated with increased misfolding of SOD1, it has previously been
shown that treatment with CuATSM did not reduce the levels of misfolded SOD1 in SOD1G37R
mice28. Interestingly, CuATSM has been shown to reduce the accumulation of abnormally
phosphorylated and fragmented TDP-43 in the spinal cords of mice expressing low levels of
mutant SOD1G93A 48. This may be due to direct effects on SOD1 aggregation as SOD1 aggregates
have been shown to induce TDP-43 mislocalisation49. Here, we show that CuATSM treatment
reduces the aggregation of pathogenic WTL SOD1 mutants and has small but nonsignificant
effects on the aggregation of MBR mutants and a small but significant effect on cells expressing
SOD1G127X. Similarly, CuATSM does not alter the minimal aggregation in cells expressing
SOD1D90A, EGFP or SOD1WT. Our data suggests that the primary effect CuATSM has on
aggregation is to supply Cu to mutant SOD1, thereby stabilizing its structure. The small reductions
in aggregation observed with mutants unable to bind Cu suggests that CuATSM could also have
additional indirect effects on aggregation by activating stress pathways via Nrf250, including the
ubiquitin-proteasome system, but that this modest effect does not extend to cell viability. In the
case of G127X, there is also a chance that since it retains the Cu-coordinating histidine residues
(H46, H48, H63, and H120), Cu could be binding with low affinity. This could afford a slight
increase in stability that plausibly translates to the minimal effect on aggregation observed here.

9

Figure 4: CuATSM decreases the aggregation of WTL SOD1 mutants. (A) NSC-34 cells transfected
with SOD1WT-EGFP or SOD1A4V-EGFP were imaged by confocal microscopy pre- and post-saponin
treatment to identify cells containing insoluble SOD1-EGFP aggregates. Scale bars are 20 µm and pink
arrowheads highlight insoluble aggregates. (B) NSC-34 cells expressing SOD1-EGFP constructs were also
imaged pre- and post-saponin treatment using an IncuCyte automated microscope to determine the
proportion of transfected cells that contained SOD1-EGFP inclusions. Data shown are mean ± SEM (n =
3). Each sample is an individually treated, single microplate well. Data are representative of 3 independent
experiments. The fold decrease in the number of cells containing aggregates seen with +CuATSM treatment
(relative to the vehicle control, -CuATSM) is stated above each mutant. Statistical significance was
determined by two-way ANOVA with a Bonferroni post-test (** p < 0.01, *** p < 0.001).

CuATSM increases SOD1 levels and activity in WT-like mutants.
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Previous work demonstrates that administration of CuATSM results in the increase of human
mutant SOD1 protein levels in mouse models of ALS27,28. The increase in SOD1 protein levels
also corresponded to an increase in SOD1 activity27 suggesting the additional protein was properly
folded and metalated. To test whether SOD1 levels and activity were increased by CuATSM in
the NSC-34 cell model used here, western blotting and in-gel zymography was performed on cell
lysates from cells cultured in the absence or presence of CuATSM. Cells expressing SOD1WT and
SOD1A4V and SOD1H46R were compared as examples of WTL and MBR mutants. In-gel
zymography revealed that CuATSM increased the activity of human SOD1 in the case of cells
expressing SOD1WT and SOD1A4V (Figure 5, Supplementary Figure 3). Similarly, CuATSM
increased the activity of SOD1D90A and all pathogenic WTL mutants tested (Supplementary
Figure 3). However, SOD1A4V remained predominantly monomeric regardless of treatment. This
increase in activity was accompanied by increases in protein levels as determined by western blot
(Figure 6, Supplementary Figure 4). In contrast, SOD1H46R was inactive in both the presence
and absence of CuATSM (Figure 5B), and there was no difference in protein levels after treatment
with CuATSM (Figure 6B). In-gel zymography results also indicate that the MBR mutant
SOD1G85R and truncation mutant SOD1G127X remain inactive regardless of CuATSM treatment
(Supplementary Figure 3).

Figure 5. CuATSM increases the activity of WT-like SOD1 mutants. (A) Lysates from NSC-34 cells
overexpressing SOD1WT, SOD1A4V and SOD1H46R were separated on native 4-16% gradient bis-tris gels
and SOD1 activity was determined by in-gel zymography. Equal loading was determined by measuring
endogenous mouse SOD1 on the same gel. (B). Quantification of SOD1 activity expressed relative to
endogenous mouse SOD1 levels. Data shown are mean ± SEM (n = 3). Data is from 3 independent
experiments. Two-way ANOVA with Bonferroni post-test was used to compare differences between cell
lysates cultured in the presence and absence of CuATSM (**p<0.01).

Large pools of Cu-deficient SOD1 have been detected in the spinal cords of SOD1G37R mice and
treatment with CuATSM reduced this pool and subsequently increased the amount of fully
metalated SOD128. Here we show that CuATSM treatment increases the concentration of active
enzyme and reduces the aggregation of SOD1 mutants in NSC-34 cells. These results suggest that,
in our system, overexpression of pathogenic WTL SOD1 mutants exceeds basal Cu demands of
the cell, creating a pool of Cu deficient SOD1 which misfolds and aggregates. Interestingly,
overexpression of SOD1WT and SOD1D90A also results in a pool of Cu deficient SOD1 as treatment
11

with CuATSM increases human SOD1 activity in NSC-34 cells, however, this does not result in
aggregation and toxicity. This is consistent with the notion that a misfolded conformer is required
for toxicity and not Cu deficiency per se. While our results suggest that misfolding and aggregation
are the common attributes of WTL and MBR mutants that are associated with toxicity, Cu
deficiency could result in the misfolding of SOD1 and subsequent aggregation and toxicity.
Indeed, as aggregated SOD1 propagates in a prion-like fashion18-21, increasing the availability of
Cu to cells could reduce the pool of misfolded SOD1 required for template driven aggregation and
thus propagation.

Figure 6. CuATSM increases the levels of WT-like SOD1 mutants. (A) Cell lysates from NSC-34 cells
overexpressing SOD1WT, SOD1A4V and SOD1H46R were separated on native 4-16% gradient bis-tris gels
and SOD1-EGFP levels were determined by western blot analysis. (B) SOD1-EGFP levels were quantified
from western blot analyses by densitometry and expressed relative to the average of the total EGFP signal
for that variant. Data shown are mean ± SEM (n = 3). Data is from 3 independent experiments. Two-way
ANOVA with Bonferroni post-test was used to compare differences between cell lysates cultured in the
presence and absence of CuATSM (*p<0.05, ***p<0.001).

Copper homeostasis is an area of growing interest in SOD1-fALS research as Cu is found to be
dysregulated in animal models expressing either WTL or MBR SOD1 mutants51-54. For example,
Cu levels are found to be increased in affected neural tissues in SOD1-fALS mouse models
including SOD1G37R, SOD1G93A, SOD1WT, and even in mice expressing the MBR double mutant
SOD1H46R/H48Q 51-54. This suggests that Cu dysregulation in the central nervous system (CNS) is a
common feature of SOD1 overexpression. The SOD1-associated Cu dysregulation in these models
has been shown to affect other Cu-binding proteins such as cytochrome c oxidase30 and
ceruloplasmin55. Although this effect appears to be partially model-specific as cytochrome c
oxidase activity was no different to controls in the latter study, this difference is likely due to the
fact that the hCCS×SOD1G93A model is an extremely severe model of the disease. Furthermore,
Cu dysregulation appears to occur early in SOD1 mouse models where changes to Cu levels in the
CNS are detected as early as 30 days of age, well before symptom onset, in SOD1G93A mice56.
Similarly, the SOD1G37R mouse model experiences a redistribution of Cu from the liver to the CNS
at the embryonic stages of development, which is not seen in adult mice57, suggesting changes to
Cu regulation over time in SOD1 mouse models.
12

Considering the above work, there have been several proposals for the molecular mechanism(s)
by which CuATSM attenuates the ALS phenotype in model systems. These proposals emphasize
the role of CuATSM in restoring healthy SOD1 folding and function, or they emphasize the role
of CuATSM in restoring Cu homeostasis to other proteins as well as SOD1. The interpretation is
made difficult because of the concomitant effects of SOD1 misfolding and Cu dysregulation.
Evidence for a homeostatic role include research in which treating a SOD1G93A mouse model with
CuATSM was shown to inhibit peroxynitrite activity48. Oxidative and nitrosative stress were also
found to be reduced, although it is unclear if this resulted from the increased folding of SOD1.
Also, the transgenic mouse line overexpressing human CCS and SOD1G93A (hCCS×SOD1G93A)
was found to have severe Cu dyshomeostasis, where treatment with CuATSM restored Cu binding
to cytochrome c oxidase30. This model also presented the curious observation that levels of
misfolded SOD1 did not decrease even though levels of Cu-bound SOD1 increased27. Other effects
of CuATSM not related to the CNS have been reported, such as upregulation of antioxidant
enzymes in human coronary artery smooth muscle cells and cardiac myocytes through activation
of the transcription factor NF-E2 related factor 2 (Nrf2)50. Finally, several Parkinson’s disease
mouse models58 were shown to have better outcomes when treated with CuATSM, consistent with
the idea that misfolded non-metalated SOD1 is not required for its protective ability in
neurodegeneration.

Figure 7: A model of CuATSM rescue of mutant SOD1 pathology. Red arrows show the folding and
off-folding pathways for SOD1, whereas blue arrows show the contribution of CuATSM to these pathways.
Arrow thickness suggests the probability of the pathways occurring. Following synthesis, mutant SOD1
(red start) folds into an intermediate state that is primed for Zn binding. Zn bound SOD1 associates with
Cu-loaded CCS for transfer of Cu, leading to the formation of a mature SOD1 monomer that can form
dimers. CuATSM results in a larger pool of Cu bound CCS which in turn results in greater transfer of Cu
to SOD1, reducing the amount of SOD1 that enters an off-folding pathway at this point.
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Our results, however, indicate distinct differences between MBR, a truncation mutation and
pathogenic WTL mutants regarding the effect of CuATSM on the toxicity, aggregation, and
maturation of SOD1 mutants in NSC-34 cells (Figure 7). This evidence supports a distinct role of
CuATSM in alleviating SOD1 aggregation and toxicity only for mutants that are capable of being
rescued. However, cultured cells do not effectively model the CNS, and it is likely that CuATSM
has multiple modes of action in the complex environment of the brain, including on cell types other
than neurons (e.g. astrocytes59). Future work examining the effect of CuATSM in SOD1 MBR
mutant transgenic mouse lines will be needed to reconcile these data. Furthermore, the role of
metals in neurodegeneration is still unclear. Most data linking aberrant metal interactions to
neurodegeneration in humans comes from ecological and occupational studies60. It is possible that
metal homeostasis, like proteostasis, declines or changes with age. More research into this
important area is necessary to determine the exact links between neurodegeneration and metal
homeostasis.
Conclusions
Our results suggest that CuATSM is protective against toxicity mediated by a range of pathogenic
WTL SOD1 mutants but not in the case of MBR mutants or a truncation mutant in a cell culture
system. These results may be relevant for the design of future clinical trials of CuATSM for MND
patients, as the disease type (fALS or sALS), and specific SOD1 mutations linked to the fALS
case, may both impact on the efficacy of the treatment.

Methods
Plasmids. The pEGFP-N1 vectors containing human SOD1 sequences were generated as
described61.
Cell culture and transfection. Neuroblastoma × Spinal cord hybrid NSC-34 cells62 were
maintained in Dulbecco’s Modified Eagles Medium/ Ham’s Nutrient Mixture F12 (DMEM/F12)
supplemented with 10% (v/v) foetal bovine serum (FBS, Bovogen Biologicals, Australia). Cells
were maintained at 37 °C in a humidified incubator with 5% (v/v) atmospheric CO2. Cells were
transiently transfected using Lipofectamine 3000 (Invitrogen, USA) according to manufacturer’s
instructions with 0.5 μg DNA per well for a 24-well plate and 2.5 μg DNA per well for 6-well
plates.
CuATSM treatment. Cu(II)ATSM (SYNthesis med chem, Parkville, VIC, Australia) was
dissolved in DMSO to make a 10 mM stock. NSC-34 cells were treated with 0 - 1 µM CuATSM
or DMSO vehicle control (diluted in culture medium) 24 h post transfection for up to 120 h.
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Time lapse imaging. The viability of cells expressing SOD1 in the presence and absence of
CuATSM was monitored over 120 h in an IncuCyte automated fluorescent microscope (Essen
BioScience, USA) as described in17. NSC-34 cells were plated into 24-well plates at a confluency
of ~ 65% and transfected with SOD1-EGFP constructs 24 h later. Cells were dissociated 24 h post
transfection and replated in clear flat-bottomed 96-well plates at a confluency of 30% in phenol
red free DMEM/F12 containing 10% FBS and 0 - 1 µM CuATSM or vehicle control (DMSO).
Images were acquired every 3 h and analysed using a processing definition created to select GFP
positive cells. The number of GFP positive cells was normalized to time zero before mutant SOD1
numbers were adjusted to SOD1WT values as previously reported17. To analyze differences
between treatments, area under the curve analysis was performed using GraphPad Prism version
5.00 for Windows (GraphPad software, USA). The percent protection score was calculated from
GFP count data normalized to t = 0 h, where the area under the curve (AUC) from t = 0 -72 h was
calculated for both vehicle control and CuATSM treated cells. The follow equation was used:
% 𝑃𝑟𝑜𝑡𝑒𝑐𝑡𝑖𝑜𝑛 = 100 ×

(𝐴𝑈𝐶 𝐶𝑢𝐴𝑇𝑆𝑀) − (𝐴𝑈𝐶 𝑉𝑒ℎ𝑖𝑐𝑙𝑒)
(𝐴𝑈𝐶 𝑉𝑒ℎ𝑖𝑐𝑙𝑒)

Saponin treatment to detect insoluble aggregates. NSC-34 cells expressing SOD1-EGFP were
gently treated 72 h post transfection with 0.03% saponin in PBS to allow the diffusion of soluble
intracellular SOD1-EGFP out of the cytoplasm to identify cells containing SOD1 aggregates45,46.
Cells were imaged pre and post saponin treatment on a TCS SP5 confocal microscope (Leica,
Germany) or by using the scan on demand function on the IncuCyte and the number of cells
containing aggregates was determined as a proportion of GFP expressing cells.
Cell lysis. NSC-34 cells grown in 6-well plates and transfected with SOD1-EGFP were harvested
48 h post CuATSM treatment (72 h post transfection) with trypsin/EDTA (Gibco, USA). Cells
were washed with PBS before being resuspended in RIPA buffer (50 mM TrisHCl pH 7.4, 1%
(w/v) sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 1% TX-100, 0.1% SDS, 10mM NEM,
1 mM sodium orthovanadate, HaltTM Protease Inhibitor Cocktail (Thermo Scientific, USA)).
Protein concentration was determined by BCA assay.
SOD1 In-gel zymography. SOD1 enzymatic activity was determined using in-gel zymography
methods described previously63. Briefly, 30 µg of cell lysate or 100 ng of purified SOD1WT protein
(prepared as previously described17) was loaded onto a NativePAGETM 4-16% gradient bis-tris gel
(Invitrogen, USA). Following electrophoresis (150 V, 3 h), gels were incubated in 5 mM
nitrotetrazolium chloride for 15 min with gentle rocking protected from the light. Gels were then
rinsed with water before incubation with 30 µM riboflavin and 10 mM tetramethylethylenediamine
(TEMED) solution for 20 min with gentle rocking in the dark. Gels were subsequently developed
by exposure to fluorescent light on a light box until a significant signal was detected (achromatic
bands). Gels were imaged on the Amersham Imager 6600RGB and band intensity was quantified
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using ImageJ 1.48v software64. SOD1-EGFP activity was subsequently determined after
normalizing signal to purified SOD1 and endogenous mouse SOD1 levels.
Western blotting. Following in-gel zymography, proteins were transferred onto a nitrocellulose
membrane (Pall Corporation, USA) using native transfer buffer (48 mM Tris, 39 mM glycine, pH
9.2 containing 0.04% (w/v) SDS). The membrane was then incubated in native transfer buffer
containing 20% methanol before detecting GFP signal by fluorescence (excitation at 460nm) on
the Amersham Imager 6600RGB. Equal loading of the gel was determined by staining membranes
with Ponceau red.
Statistical analyses. Normally distributed data sets were analyzed for statistical significance via
the following tests: one-way ANOVA with a Tukey’s multiple comparison post-test when
comparing the means of multiple data sets, and two-way ANOVA with Bonferroni post-test when
assessing multiple variables.
AUTHOR INFORMATION
Corresponding Author
*E-mail: jyerbury@uow.edu.au
Author Contributions
MRY performed experiments, analyzed data and wrote the initial manuscript. LM designed
experiments, analyzed data and edited the manuscript. SP provided feedback on experimental
results and edited the manuscript. NEF designed experiments, performed experiments, analyzed
data and wrote and edited the manuscript. JJY conceived of the study, designed experiments,
analyzed data and edited the manuscript.
Notes
The authors do not declare any competing interests.

ACKNOWLEDGMENTS

16

The authors gratefully acknowledge Senior Professor Mark Wilson who helped with editing and
proofreading the manuscript. JJY is supported by an NHMRC Career Development Fellowship
(1084144) and both JJY and NEF were supported by a Dementia Teams Grant (1095215). MRY
would like to acknowledge the Faculty of Science, Medicine and Health, University of
Wollongong for the opportunity to undertake an internship. LM and SP were supported by
Canadian Institutes of Health Research Transitional Operating Grant 2682.

REFERENCES
1
2
3
4
5
6
7
8
9
10
11
12

Kiernan, M. C. et al. Amyotrophic lateral sclerosis. Lancet 377, 942-955,
doi:10.1016/S0140-6736(10)61156-7 (2011).
Andersen, P. M. & Al-Chalabi, A. Clinical genetics of amyotrophic lateral sclerosis: what
do we really know? Nat. Rev. Neurol. 7, 603-615, doi:10.1038/nrneurol.2011.150 (2011).
Rosen, D. R. et al. Mutations in Cu/Zn superoxide dismutase gene are associated with
familial amyotrophic lateral sclerosis. Nature 362, 59-62, doi:10.1038/362059a0 (1993).
Neumann, M. et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and
amyotrophic lateral sclerosis. Science 314, 130-133, doi:10.1126/science.1134108
(2006).
Kwiatkowski, T. J., Jr. et al. Mutations in the FUS/TLS gene on chromosome 16 cause
familial
amyotrophic
lateral
sclerosis.
Science
323,
1205-1208,
doi:10.1126/science.1166066 (2009).
Vance, C. et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic
lateral sclerosis type 6. Science 323, 1208-1211, doi:10.1126/science.1165942 (2009).
Williams, K. L. et al. CCNF mutations in amyotrophic lateral sclerosis and frontotemporal
dementia. Nat. Commun. 7, 11253, doi:10.1038/ncomms11253 (2016).
DeJesus-Hernandez, M. et al. Expanded GGGGCC hexanucleotide repeat in noncoding
region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245-256,
doi:10.1016/j.neuron.2011.09.011 (2011).
Renton, A. E. et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of
chromosome
9p21-linked
ALS-FTD.
Neuron
72,
257-268,
doi:10.1016/j.neuron.2011.09.010 (2011).
Taylor, J. P., Brown, R. H., Jr. & Cleveland, D. W. Decoding ALS: from genes to
mechanism. Nature 539, 197-206, doi:10.1038/nature20413 (2016).
Valentine, J. S., Doucette, P. A. & Potter, S. Z. COPPER-ZINC SUPEROXIDE
DISMUTASE AND AMYOTROPHIC LATERAL SCLEROSIS. Annu. Rev. Biochem. 74,
563-593, doi:10.1146/annurev.biochem.72.121801.161647 (2005).
Leinartaite, L., Saraboji, K., Nordlund, A., Logan, D. T. & Oliveberg, M. Folding catalysis
by transient coordination of Zn2+ to the Cu ligands of the ALS-associated enzyme Cu/Zn
superoxide dismutase 1. J. Am. Chem. Soc. 132, 13495-13504, doi:10.1021/ja1057136
(2010).

17

13
14
15
16
17
18

19
20
21

22

23
24
25
26
27
28

Banci, L. et al. Human superoxide dismutase 1 (hSOD1) maturation through interaction
with human copper chaperone for SOD1 (hCCS). Proc. Natl. Acad. Sci. U. S. A. 109,
13555-13560, doi:10.1073/pnas.1207493109 (2012).
McCord, J. M. & Fridovich, I. Superoxide dismutase. An enzymic function for
erythrocuprein (hemocuprein). J. Biol. Chem. 244, 6049-6055 (1969).
Gurney, M. et al. Motor neuron degeneration in mice that express a human Cu,Zn
superoxide dismutase mutation. Science 264, 1772-1775, doi:10.1126/science.8209258
(1994).
Giordana, M. T. et al. TDP-43 redistribution is an early event in sporadic amyotrophic
lateral sclerosis. Brain Pathol. 20, 351-360, doi:10.1111/j.1750-3639.2009.00284.x
(2010).
McAlary, L., Aquilina, J. A. & Yerbury, J. J. Susceptibility of Mutant SOD1 to Form a
Destabilized Monomer Predicts Cellular Aggregation and Toxicity but Not Aggregation
Propensity. Front. Neurosci. 10, 499, doi:10.3389/fnins.2016.00499 (2016).
Grad, L. I., Pokrishevsky, E., Silverman, J. M. & Cashman, N. R. Exosome-dependent and
independent mechanisms are involved in prion-like transmission of propagated Cu/Zn
superoxide dismutase misfolding. Prion 8, 331-335, doi:10.4161/19336896.2014.983398
(2014).
Zeineddine, R. et al. SOD1 protein aggregates stimulate macropinocytosis in neurons to
facilitate their propagation. Mol. Neurodegener. 10, 57, doi:10.1186/s13024-015-0053-4
(2015).
Grad, L. I. et al. Intermolecular transmission of superoxide dismutase 1 misfolding in living
cells. Proc. Natl. Acad. Sci. U. S. A. 108, 16398-16403, doi:10.1073/pnas.1102645108
(2011).
Grad, L. I. et al. Intercellular propagated misfolding of wild-type Cu/Zn superoxide
dismutase occurs via exosome-dependent and -independent mechanisms. Proceedings
of the National Academy of Sciences 111, 3620-3625, doi:10.1073/pnas.1312245111
(2014).
Lindberg, M. J., Tibell, L. & Oliveberg, M. Common denominator of Cu/Zn superoxide
dismutase mutants associated with amyotrophic lateral sclerosis: decreased stability of
the apo state. Proc. Natl. Acad. Sci. U. S. A. 99, 16607-16612,
doi:10.1073/pnas.262527099 (2002).
Oztug Durer, Z. A. et al. Loss of metal ions, disulfide reduction and mutations related to
familial ALS promote formation of amyloid-like aggregates from superoxide dismutase.
PLoS One 4, e5004, doi:10.1371/journal.pone.0005004 (2009).
McAlary, L., Yerbury, J. J. & Aquilina, J. A. Glutathionylation potentiates benign
superoxide dismutase 1 variants to the toxic forms associated with amyotrophic lateral
sclerosis. Sci. Rep. 3, 3275, doi:10.1038/srep03275 (2013).
Das, A. & Plotkin, S. S. Mechanical probes of SOD1 predict systematic trends in metal
and dimer affinity of ALS-associated mutants. J. Mol. Biol. 425, 850-874,
doi:10.1016/j.jmb.2012.12.022 (2013).
Ciryam, P. et al. Spinal motor neuron protein supersaturation patterns are associated with
inclusion body formation in ALS. Proc. Natl. Acad. Sci. U. S. A. 114, E3935-E3943,
doi:10.1073/pnas.1613854114 (2017).
Hilton, J. B. et al. CuII(atsm) improves the neurological phenotype and survival of
SOD1G93A mice and selectively increases enzymatically active SOD1 in the spinal cord.
Sci. Rep. 7, doi:10.1038/srep42292 (2017).
Roberts, B. R. et al. Oral treatment with Cu(II)(atsm) increases mutant SOD1 in vivo but
protects motor neurons and improves the phenotype of a transgenic mouse model of
amyotrophic
lateral
sclerosis.
J.
Neurosci.
34,
8021-8031,
doi:10.1523/JNEUROSCI.4196-13.2014 (2014).

18

29
30
31
32
33
34
35
36
37
38
39
40

41

42

43
44
45

McAllum, E. J. et al. Therapeutic effects of CuII(atsm) in the SOD1-G37R mouse model
of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Frontotemporal Degener. 14,
586-590, doi:10.3109/21678421.2013.824000 (2013).
Williams, J. R. et al. Copper delivery to the CNS by CuATSM effectively treats motor
neuron disease in SOD(G93A) mice co-expressing the Copper-Chaperone-for-SOD.
Neurobiol. Dis. 89, 1-9, doi:10.1016/j.nbd.2016.01.020 (2016).
Farrawell, N. E. et al. SOD1 aggregation alters ubiquitin homeostasis in a cell model of
ALS. J. Cell Sci. 131, doi:10.1242/jcs.209122 (2018).
Farrawell, N. E. et al. Distinct partitioning of ALS associated TDP-43, FUS and SOD1
mutants into cellular inclusions. Sci. Rep. 5, 13416, doi:10.1038/srep13416 (2015).
Strange, R. W. et al. The Structure of Holo and Metal-deficient Wild-type Human Cu, Zn
Superoxide Dismutase and its Relevance to Familial Amyotrophic Lateral Sclerosis. J.
Mol. Biol. 328, 877-891, doi:10.1016/s0022-2836(03)00355-3 (2003).
Vieira, F. G. et al. CuATSM efficacy is independently replicated in a SOD1 mouse model
of ALS while unmetallated ATSM therapy fails to reveal benefits. IBRO Reports 2, 47-53,
doi:10.1016/j.ibror.2017.03.001 (2017).
Al-Chalabi, A. Recessive amyotrophic lateral sclerosis families with the D90A SOD1
mutation share a common founder: evidence for a linked protective factor. Hum. Mol.
Genet. 7, 2045-2050, doi:10.1093/hmg/7.13.2045 (1998).
Parton, M. J. et al. D90A-SOD1 mediated amyotrophic lateral sclerosis: a single founder
for all cases with evidence for a Cis-acting disease modifier in the recessive haplotype.
Hum Mutat 20 (2002).
Andersen, P. M. et al. Autosomal recessive adult-onset amyotrophic lateral sclerosis
associated with homozygosity for Asp90Ala CuZn-superoxide dismutase mutation. A
clinical and genealogical study of 36 patients. Brain 119, 1153-1172 (1996).
Felbecker, A. et al. Four familial ALS pedigrees discordant for two SOD1 mutations: are
all SOD1 mutations pathogenic? J Neurol Neurosurg Psychiatry 81, 572-577 (2010).
Ratovitski, T. et al. Variation in the biochemical/biophysical properties of mutant
superoxide dismutase 1 enzymes and the rate of disease progression in familial
amyotrophic lateral sclerosis kindreds. Hum. Mol. Genet. 8, 1451-1460 (1999).
Rodriguez, J. A. et al. Familial amyotrophic lateral sclerosis-associated mutations
decrease the thermal stability of distinctly metallated species of human copper/zinc
superoxide dismutase. J. Biol. Chem. 277, 15932-15937, doi:10.1074/jbc.M112088200
(2002).
Rumfeldt, J. A. O., Stathopulos, P. B., Chakrabarrty, A., Lepock, J. R. & Meiering, E. M.
Mechanism and thermodynamics of guanidinium chloride-induced denaturation of ALSassociated mutant Cu,Zn superoxide dismutases. J. Mol. Biol. 355, 106-123,
doi:10.1016/j.jmb.2005.10.042 (2006).
Furukawa, Y., Kaneko, K., Yamanaka, K., O'Halloran, T. V. & Nukina, N. Complete loss
of post-translational modifications triggers fibrillar aggregation of SOD1 in the familial form
of
amyotrophic
lateral
sclerosis.
J.
Biol.
Chem.
283,
24167-24176,
doi:10.1074/jbc.M802083200 (2008).
Stathopulos, P. B. et al. Calorimetric analysis of thermodynamic stability and aggregation
for apo and holo amyotrophic lateral sclerosis-associated Gly-93 mutants of superoxide
dismutase. J. Biol. Chem. 281, 6184-6193, doi:10.1074/jbc.M509496200 (2006).
Luchinat, E., Barbieri, L. & Banci, L. A molecular chaperone activity of CCS restores the
maturation of SOD1 fALS mutants. Sci. Rep. 7, 17433, doi:10.1038/s41598-017-17815-y
(2017).
Pokrishevsky, E. et al. Tryptophan 32-mediated SOD1 aggregation is attenuated by
pyrimidine-like compounds in living cells. Sci Rep 8, 15590, doi:10.1038/s41598-01832835-y (2018).

19

46
47
48

49
50
51

52

53
54
55

56
57
58
59
60
61
62

Prudencio, M. & Borchelt, D. R. Superoxide dismutase 1 encoding mutations linked to ALS
adopts a spectrum of misfolded states. Mol Neurodegener 6, 77, doi:10.1186/1750-13266-77 (2011).
Whiten, D. R. et al. Rapid flow cytometric measurement of protein inclusions and nuclear
trafficking. Sci. Rep. 6, 31138, doi:10.1038/srep31138 (2016).
Soon, C. P. W. et al. Diacetylbis(N(4)-methylthiosemicarbazonato) Copper(II) (CuII(atsm))
Protects against Peroxynitrite-induced Nitrosative Damage and Prolongs Survival in
Amyotrophic Lateral Sclerosis Mouse Model. J. Biol. Chem. 286, 44035-44044,
doi:10.1074/jbc.m111.274407 (2011).
Zeineddine, R., Farrawell, N. E., Lambert-Smith, I. A. & Yerbury, J. J. Addition of
exogenous SOD1 aggregates causes TDP-43 mislocalisation and aggregation. Cell
Stress Chaperones 22, 893-902, doi:10.1007/s12192-017-0804-y (2017).
Srivastava, S. et al. Cardioprotective effects of CuATSM in human vascular smooth
muscle cells and cardiomyocytes mediated by Nrf2 and DJ-1. Sci. Rep. 6, 7,
doi:10.1038/s41598-016-0012-5 (2016).
Tokuda, E., Okawa, E., Watanabe, S., Ono, S.-I. & Marklund, S. L. Dysregulation of
intracellular copper homeostasis is common to transgenic mice expressing human mutant
superoxide dismutase-1s regardless of their copper-binding abilities. Neurobiol. Dis. 54,
308-319, doi:10.1016/j.nbd.2013.01.001 (2013).
Tokuda, E., Okawa, E. & Ono, S.-I. Dysregulation of intracellular copper trafficking
pathway in a mouse model of mutant copper/zinc superoxide dismutase-linked familial
amyotrophic lateral sclerosis. J. Neurochem. 111, 181-191, doi:10.1111/j.14714159.2009.06310.x (2009).
Tokuda, E. et al. Metallothionein proteins expression, copper and zinc concentrations, and
lipid peroxidation level in a rodent model for amyotrophic lateral sclerosis. Toxicology 229,
33-41, doi:10.1016/j.tox.2006.09.011 (2007).
Lelie, H. L. et al. Copper and zinc metallation status of copper-zinc superoxide dismutase
from amyotrophic lateral sclerosis transgenic mice. J. Biol. Chem. 286, 2795-2806,
doi:10.1074/jbc.M110.186999 (2011).
Hilton, J. B., Kysenius, K., White, A. R. & Crouch, P. J. The accumulation of enzymatically
inactive cuproenzymes is a CNS-specific phenomenon of the SOD1G37R mouse model
of ALS and can be restored by overexpressing the human copper transporter hCTR1. Exp.
Neurol. 307, 118-128, doi:10.1016/j.expneurol.2018.06.006 (2018).
Enge, T. G., Ecroyd, H., Jolley, D. F., Yerbury, J. J. & Dosseto, A. Longitudinal assessment
of metal concentrations and copper isotope ratios in the G93A SOD1 mouse model of
amyotrophic lateral sclerosis. Metallomics 9, 161-174, doi:10.1039/c6mt00270f (2017).
Kysenius, K., Hilton, J. B., Paul, B., Hare, D. J. & Crouch, P. J. Anatomical redistribution
of endogenous copper in embryonic mice overexpressing SOD1. Metallomics,
doi:10.1039/c8mt00242h (2018).
Hung, L. W. et al. The hypoxia imaging agent CuII(atsm) is neuroprotective and improves
motor and cognitive functions in multiple animal models of Parkinson's disease. J. Exp.
Med. 209, 837-854, doi:10.1084/jem.20112285 (2012).
Liddell, J. Are Astrocytes the Predominant Cell Type for Activation of Nrf2 in Aging and
Neurodegeneration? Antioxid. Redox Signal. 6, 65, doi:10.3390/antiox6030065 (2017).
Cicero, C. E. et al. Metals and neurodegenerative diseases. A systematic review. Environ.
Res. 159, 82-94, doi:10.1016/j.envres.2017.07.048 (2017).
Turner, B. J. et al. Impaired extracellular secretion of mutant superoxide dismutase 1
associates with neurotoxicity in familial amyotrophic lateral sclerosis. J. Neurosci. 25, 108117, doi:10.1523/JNEUROSCI.4253-04.2005 (2005).
Cashman, N. R. et al. Neuroblastoma x spinal cord (NSC) hybrid cell lines resemble
developing motor neurons. Dev. Dyn. 194, 209-221, doi:10.1002/aja.1001940306 (1992).

20

63
64

Beauchamp, C. & Fridovich, I. Superoxide dismutase: improved assays and an assay
applicable to acrylamide gels. Anal. Biochem. 44, 276-287 (1971).
Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image
analysis. Nat. Methods 9, 671-675 (2012).

21

CuATSM protects against the in vitro cytotoxicity of wild type-like
SOD1 mutants but not mutants that disrupt metal binding.
Natalie E. Farrawell1,2, Maddison R. Yerbury1,2, Steven S. Plotkin3,4, Luke McAlary3,5,
Justin J. Yerbury1,2,*
1. Illawarra Health and Medical Research Institute, Wollongong, NSW, Australia
2. School of Biological Sciences, Centre of Medicine and Molecular Biosciences, Faculty
of Science, Medicine and Health, University of Wollongong, NSW, Australia
3. Department of Physics & Astronomy, University of British Columbia, Vancouver,
BC, Canada
4. Genome Sciences and Technology Program, University of British Columbia,
Vancouver, BC, Canada
5. Djavad Mowafaghian Centre for Brain Health, University of British Columbia,
Vancouver, BC, Canada

Supporting Information

Supplementary Table 1. Summary of SOD1 mutant characteristics and the effect of CuATSM
measured in this paper
SOD1
Mutant
and class

Mutation Effects on
stability (apo S-S state)
compared to wild type

Mutation
Effect on
metal binding

Mutation Toxicity
(% survival
compared to WT)

CuATSM
Protection Score
(% protection)

Fold reduction
in aggregation
by CuATSM

Mean Disease
Duration
(years)

A4V
WTL

↓↓↓- Monomer
↓↓↓↓ Dimer

↓--- Zn
↓↓-- Cu

35.7

69.4

2.8

1.2
(n=205)

C6G
WTL

(n/a) Monomer
(n/a) Dimer

(n/a) Zn
(n/a) Cu

45.3

57.4

3.4

0.2
(n=2)

G37R
WTL

↓↓-- Monomer
↓↓-- Dimer

↓--- Zn
↓--- Cu

42.2

81.6

3.3

17.0
(n=37)

H46R
MBR

↑--- Monomer
---- Dimer

↓--- Zn
↓↓↓↓ Cu

59.7

- 2.5

1.2

17.6
(n=49)

G85R
MBR

↓↓↓- Monomer
↓↓↓- Dimer

↓↓-- Zn
↓↓↓- Cu

33.6

0.7

1.1

6.0
(n=11)

D90A
WTL

↓--- Monomer
---- Dimer

---- Zn
---- Cu

93.0

- 1.6

1.2

8.0*
(n=15)

G93A
WTL

↓↓↓- Monomer
↓↓↓- Dimer

---- Zn
---- Cu

36.1

85.9

2.5

3.1
(n=16)

E100G
WTL

↓↓-- Monomer
↓↓-- Dimer

---- Zn
---- Cu

44.5

80.0

3.5

4.7
(n=50)

G127X
truncation

↓↓↓↓ Monomer
↓↓↓↓ Dimer

(n/a) Zn
(n/a) Cu

30

- 6.6

1.3

2.8
(n=3)

V148G
WTL

↓↓↓- Monomer
↓↓↓- Dimer

(n/a) Zn
(n/a) Cu

39.1

53.6

2.2

2.1
(n=11)

References for SOD1 stabilities - 1-3
References for SOD1 metalation - 4-6
References for SOD1-fALS survival - 7,8
* the clinical severity of heterozygous D90A mutation is contested with some arguing its clinical
relevance9 and others that it is a common variant in some populations10, while others argue another
genetic element is responsible for ALS in D90A kindreds11.

1

Supplementary Figure 1: Correlations of patient mean disease duration against cell survival and
inclusion formation. The mean values of patient survival were taken from Wang et al (2008)7 and plotted
against the mean values from the data collected in this work for cell survival (left) and cells containing
inclusions (right). Solid lines indicate the fit through all SOD1 mutant data points, whereas dotted lines
indicate the removal of D90A and C6G from the fit. Data were fitted with least squares linear regression
and the R2 and p values are shown on each panel.

Supplementary Figure 2: Patient disease duration does not correlate with CuATSM protection. The
mean values of patient survival were taken from Wang et al (2008)7 and plotted against the percent
protection values from the data collected in this work for only WT-like mutants (solid line) and all mutants
(dotted line). Data were fitted with least squares linear regression and the R2 and p values are shown next
to each fit.

2

Supplementary Figure 3: (A) Cell lysates from NSC-34 cells overexpressing SOD1-GFP, as well as
untransfected cells (UT) and purified SOD1WT protein were separated on native 4-16% gradient bis-tris gels
and SOD1 activity was determined by in-gel zymography. (B) Levels of SOD1 activity were also
determined for cell lysates expressing SOD1C6G, SOD1D90A, SOD1E100G, SOD1G37R, SOD1G93A, SOD1G85R,
SOD1G127X and SOD1V148G by in-gel zymography. Data shown are for n = 1.

3

Supplementary Figure 4: (A) Representative western blot image of the effects of CuATSM treatment on
SOD1 levels in cell lysates from NSC-34 cells overexpressing SOD1WT, SOD1A4V, or SOD1H46R, as well as
untransfected cells (UT) and purified SOD1WT protein separated on a native 4-16% gradient bis-tris gel. (B)
Equal loading of the gel was determined by staining the membrane with ponceau red.
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